VENICE, Italy and CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced additional positive efficacy data on AP23573 – its novel mTOR inhibitor – from further analysis of its ongoing Phase 2 trial of AP23573 in patients with metastatic and/or unresectable bone and soft-tissue sarcomas. The expanded analysis focuses on the 61 patients with an AP23573 clinical-benefit response – the primary end-point of the 212-patient trial – and its relation to progression-free survival.
